Valuation: Entrada Therapeutics, Inc.

Market Cap 219M 192M 179M 165M 309M 20.93B 314M 2.12B 831M 10.38B 822M 805M 35.86B P/E 2026 *
-1.5x
P/E 2027 * -1.6x
Enterprise Value 126M 110M 103M 94.41M 177M 12B 180M 1.22B 477M 5.95B 472M 461M 20.56B EV / Sales 2026 *
8.38x
EV / Sales 2027 * -3.77x
Free-Float
85.73%
Yield 2026 *
-
Yield 2027 * -
1 day-4.11%
1 week-9.75%
Current month-20.79%
1 month-24.38%
3 months-54.77%
6 months-47.71%
Current year-43.29%
1 week 5.72
Extreme 5.72
6.5
1 month 5.72
Extreme 5.72
8.1
Current year 5.63
Extreme 5.63
16.45
1 year 4.93
Extreme 4.93
16.45
3 years 4.93
Extreme 4.93
21.79
5 years 4.93
Extreme 4.93
36.85
10 years 4.93
Extreme 4.93
36.85
Manager TitleAgeSince
Chief Executive Officer 50 01/08/2017
Director of Finance/CFO 47 01/11/2020
President 56 01/01/2024
Director TitleAgeSince
Director/Board Member 67 01/12/2020
Director/Board Member 66 04/05/2021
Director/Board Member 59 01/09/2023
Date Insider Type Main position Quantity % Market Cap.
10/06/26 Free

Director

19,000 0.0489%
10/06/26 Free

Director

19,000 0.0489%
10/06/26 Free

Director

19,000 0.0489%
Change 5-day change 1-year change 3-year change Capi.($)
-4.44%-9.75%-6.42%-66.26% 219M
-2.25%+2.44%+53.17%+64.57% 56.19B
-1.32%-0.97%+38.41%+77.52% 54.83B
+10.98%-0.25%-18.35%-14.27% 23.04B
-0.88%-4.09%+2.39%+387.96% 22.7B
-0.21%+0.84%+22.48%-7.92% 20.23B
0.00%+3.30%+28.01%-29.07% 17.83B
-0.97%+0.89%+37.28%+539.62% 15.65B
-6.69%-5.11%+166.00%+304.89% 15.24B
-0.07%+0.71%+27.33%+184.74% 14.03B
Average -1.37%-0.43%+35.03%+144.18% 23.99B
Weighted average by Cap. -1.21%+0.41%+38.23%+130.64%

Financials

2026 *2027 *
Net sales 14.99M 13.15M 12.25M 11.27M 21.12M 1.43B 21.48M 145M 56.88M 710M 56.27M 55.06M 2.45B 29.81M 26.16M 24.36M 22.41M 42M 2.85B 42.72M 289M 113M 1.41B 112M 109M 4.88B
Net income -176M -154M -144M -132M -248M -16.8B -252M -1.7B -667M -8.33B -660M -646M -28.78B -188M -165M -153M -141M -264M -17.92B -269M -1.82B -712M -8.89B -704M -689M -30.71B
Net Debt -93.49M -82.05M -76.4M -70.27M -132M -8.93B -134M -906M -355M -4.43B -351M -343M -15.3B -331M -291M -271M -249M -467M -31.66B -475M -3.21B -1.26B -15.7B -1.24B -1.22B -54.26B
Logo Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in establishing a class of medicines, which engages intracellular targets. Its Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. The Company is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. The Company is focused on the development of EEV therapeutics for rare neuromuscular diseases, including Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1. The Company has advanced two ocular programs into lead optimization for the potential treatment of inherited retinal diseases.
Employees
152
Date Price Change Volume
28/07/26 $5.810 -4.44% 352,986
27/07/26 $6.080 +3.93% 446,761
24/07/26 $5.850 -3.31% 566,335
23/07/26 $6.050 -1.63% 791,911
22/07/26 $6.150 -4.80% 375,955
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
6.080USD
Average target price
18.75USD
Spread / Average Target
+208.39%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TRDA Stock